CAMBRIDGE, UK – August, 2025 – AbOliGo, a biotechnology company pioneering high-performance antibody-oligonucleotide conjugates (AOCs), today announced the successful close of an oversubscribed seed funding round. The raise attracted strong support from leading early-stage life sciences investors and will enable AbOliGo to scale manufacturing, expand its team, and drive commercial growth.

Multiomic applications such as spatial biology, proteomics, and single-cell analysis which incorporate AOCs, continue to be widely adopted. Despite over 7 million RUO antibodies available in the market, fewer than 0.1 percent are offered as AOCs which will hinder scientific discovery. AbOliGo is focused on solving this critical bottleneck through developing a conjugation platform which will deliver fast, reproducible, and customizable AOCs, transforming how researchers access these critical reagents.

“This investment enables us to develop and build the infrastructure needed to serve researchers pushing the frontiers of multiomic science,” said Dr. Brian Carpenter, CEO and Co-founder of AbOliGo. “Our mission is to empower scientists by providing fast, reproducible, antibody-oligo conjugates (AOCs) for all.’

Accelerating technical and commercial execution

AbOliGo will deploy the funds to achieve key milestones across innovation, manufacturing, and go-to-market efforts:

• Miniaturized Process Development – Scaling down conjugation protocols to use as little as 10 μg of antibody input, allowing access to rare and costly antibodies.
• Semi-Automated Manufacturing – Establishing a semi-automated platform to increase throughput, precision, and reproducibility.
• Commercial Expansion – Building a dedicated marketing, business development and manufacturing scientific team to support the launch of custom conjugation services, followed by a broader product offering.

Formation of expert board of directors

AbOliGo also announced the formation of its Board of Directors, composed of accomplished leaders in the life sciences reagents space:

• Nick Hutchings (AbOliGo Chairman), Founder of Absolute Antibody and Everest Biotech (both acquired by LSBio and now part of Vector Laboratories)
• Dr. Nick Gee (AbOliGo Non-Executive Director), former CEO of Innova Biosciences and inventor of the Lightning-Link conjugation technology (acquired by Expedeon/SYGNIS and now sold by Abcam).
• Karen Padgett (AbOliGo Non-Executive Director), former Founder & CEO at Novus Biologicals (acquired by Biotechne) and advisor to numerous biotech ventures.

“AbOliGo is building a truly enabling technology platform,” said Nick Hutchings. “The company has the opportunity to reshape how researchers access high-quality AOCs at scale.”

“Having scaled several reagent businesses, I can say AbOliGo is on a strong trajectory,” added Dr. Nick Gee. “We’ve engineered a solution that removes friction for both research and translational labs.”

“The combination of speed, reproducibility, and customizability is exactly what the market needs,” said Karen Padgett. “I’m excited to help guide their commercial strategy.”